Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4570
Source ID: NCT00388518
Associated Drug: Actos
Title: A Study of Aleglitazar in Patients With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: Actos|DRUG: Placebo|DRUG: aleglitazar
Outcome Measures: Primary: Absolute change from baseline in Hemoglobin A1c (HbA1c), 16 weeks | Secondary: Absolute change from baseline in Fasting Plasma Glucose (FPG), HbA1c response rate, insulin sensitivity, beta cell function and cardiovascular markers., 16 weeks|Adverse Events (AEs), laboratory parameters., Throughout study
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 332
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2006-11
Completion Date: 2008-03
Results First Posted:
Last Update Posted: 2016-11-02
Locations: Phoenix, Arizona, 85006, United States|Phoenix, Arizona, 85029, United States|Beverly Hills, California, 90211, United States|Palm Springs, California, 92262, United States|San Diego, California, 92161, United States|Chiefland, Florida, 32626, United States|Hollywood, Florida, 33023, United States|West Palm Beach, Florida, 33401, United States|Augusta, Georgia, 30909, United States|Idaho Falls, Idaho, 83404, United States|Chicago, Illinois, 60611, United States|Baton Rouge, Louisiana, 70809, United States|Baltimore, Maryland, 21229, United States|Olive Branch, Mississippi, 38654, United States|Hamilton, New Jersey, 08610, United States|New Hyde Park, New York, 11042, United States|Johnson City, Tennessee, 37604, United States|Spokane, Washington, 99216, United States|Athens, 12462, Greece|Thessaloniki, 56429, Greece|Hong Kong, Hong Kong|Bologna, 40138, Italy|Genova, 16132, Italy|Napoli, 80100, Italy|Olbia, 07026, Italy|Pavia, 27100, Italy|Perugia, 06126, Italy|Roma, 00133, Italy|Siena, 53100, Italy|Torino, 10126, Italy|Aguascalientes, 20230, Mexico|Chihuahua, 31238, Mexico|Cuernavaca, 62250, Mexico|Durango, 34080, Mexico|Guadalajara, 44340, Mexico|Guadalajara, 44650, Mexico|Mexico City, 10700, Mexico|Monterrey, 66260, Mexico|Pachuca, 42086, Mexico|Bucharest, 020475, Romania|Bucharest, Romania|Cluj-napoca, 400006, Romania|Galati, 800352, Romania|Ploiesti, 100163, Romania|Moscow, 117036, Russian Federation|Moscow, 125315, Russian Federation|Moscow, 129090, Russian Federation|Moscow, 129110, Russian Federation|Moscow, 129327, Russian Federation|Saratov, 410038, Russian Federation|St Petersburg, 197089, Russian Federation|St Petersburg, 197198, Russian Federation|Belgrade, 11000, Serbia|Kragujevac, 34000, Serbia|NIS, 18000, Serbia
URL: https://clinicaltrials.gov/show/NCT00388518

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D336 Pioglitazone small molecule DB01132 Details